Fulcrum Therapeutics Terminates Material Agreement
Ticker: FULC · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $80.0 million, $975.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-agreement
TL;DR
Fulcrum Therapeutics just terminated a big deal. Big changes coming?
AI Summary
Fulcrum Therapeutics, Inc. announced on December 18, 2024, the termination of a material definitive agreement. The company, located at 26 Landsdowne Street, Cambridge, MA, is involved in the pharmaceutical preparations industry.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty and potential financial repercussions for the company.
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Registrant
- December 18, 2024 (date) — Date of earliest event reported
- 26 Landsdowne Street, Cambridge, MA 02139 (location) — Principal executive offices
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification
FAQ
What was the specific material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify the name or details of the agreement.
What are the reasons for the termination of this agreement?
The provided text does not disclose the specific reasons behind the termination of the material definitive agreement.
When did the termination of the agreement become effective?
The earliest event reported is December 18, 2024, which is the date of the report and the date as of which the change occurred, implying the termination was effective around this date.
Will this termination have a significant financial impact on Fulcrum Therapeutics?
The filing does not provide specific details on the financial impact of the termination, but the nature of a 'material definitive agreement' suggests it could be significant.
Are there any other agreements or partnerships that are affected by this termination?
The filing does not mention any other agreements or partnerships being affected by this specific termination.
Filing Stats: 884 words · 4 min read · ~3 pages · Grade level 14 · Accepted 2024-12-23 16:30:54
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share FULC Nasdaq Global Market
- $80.0 million — ment, Sanofi made an upfront payment of $80.0 million to Fulcrum. Fulcrum was also eligible t
- $975.0 million — eligible to receive up to an additional $975.0 million in specified regulatory and sales-based
Filing Documents
- d911298d8k.htm (8-K) — 27KB
- 0001193125-24-284214.txt ( ) — 148KB
- fulc-20241218.xsd (EX-101.SCH) — 3KB
- fulc-20241218_lab.xml (EX-101.LAB) — 18KB
- fulc-20241218_pre.xml (EX-101.PRE) — 11KB
- d911298d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits Exhibit No. Description 10.1 Collaboration and License Agreement, dated as of May 11, 2024, by and between Fulcrum and Genzyme Corporation, Inc, a wholly-owned subsidiary of Sanofi (incorporated by reference to Exhibit 10.1 to Fulcrum's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on July 31, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Certain portions of this exhibit have been omitted because the registrant has determined that they are both not material and is the type of information that the registrant treats as private or confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date: December 23, 2024 By: /s/ Alex C. Sapir Name: Alex C. Sapir Title: President and Chief Executive Officer